Investigation of Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 MR Tablet Dose in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight- Matched Healthy Subjects in a Single Center, Non-controlled, Open-label, Observational Design
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2019
At a glance
- Drugs BAY 1101042 (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors Bayer
- 07 Dec 2018 Planned End Date changed from 22 Nov 2018 to 22 Jan 2019.
- 22 Oct 2018 Planned primary completion date changed from 15 Oct 2018 to 30 Oct 2018.
- 22 Oct 2018 Status changed from recruiting to active, no longer recruiting.